オプションチェーンは、Namib Mineralsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Namib Mineralsの市場センチメントを評価します。.

Namib Minerals (NASDAQ:NAMMW) 株価情報, オプションチェーン

Namib Minerals is a gold producer, developer and explorer with operations focused in Zimbabwe.

Namib Minerals

<a href="https://www.transportation.gov/briefing-room/us-transportation-secretary-sean-p-duffy-announces-faa-international-partners-will" title="https://www.transportation.gov/briefing-room/us-transportation-secretary-sean-p-duffy-announces-faa-international-partners-will">https://www.transportation.gov/briefing-room/us-transportation-secretary-sean-p-duffy-announces-faa-international-partners-will</a>

News

ACHR

JOBY

'U.S. Transportation Secretary Sean P. Duffy Announces FAA, International Partners Will Collaborate On Advanced Air Mobility' - DOT

UBS analyst Colin Bristow maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $12 to $5.

Price Target

Analyst Ratings

RCKT

UBS Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $5

Earnings

Earnings Beats

Tsakos Energy Navigation Q1 EPS $1.04 Compared With $1.60 YoY, Sales $197.05M Lower Than $201.589M YoY

<a href="https://www.bloomberg.com/news/articles/2025-06-17/musk-s-xai-in-talks-to-raise-4-3-billion-in-equity-funding" title="https://www.bloomberg.com/news/articles/2025-06-17/musk-s-xai-in-talks-to-raise-4-3-billion-in-equity-funding">https://www.bloomberg.com/news/articles/2025-06-17/musk-s-xai-in-talks-to-raise-4-3-billion-in-equity-funding</a>

AMZN

GOOG

GOOGL

MSFT

'Musk's xAI In Talks To Raise $4.3 Billion In Equity Funding' - Bloomberg News

UBS analyst William Appicelli maintains Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) with a Buy and raises the price target from $160 to $207.

UBS Maintains Buy on Vistra, Raises Price Target to $207

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan analyst Anthony Paolone downgraded FrontView REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) from Overweight to Neutral and lowered the price target from $14 to $12. FrontView REIT shares closed at $11.54 on Monday. <a href="https://www.benzinga.com/quote/fvr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Andres Coello downgraded the rating for Millicom International Cellular S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGO#NASDAQ">TIGO</a>) from Sector Outperform to Sector Perform and announced a $37 price target. Millicom Intl Cellular shares closed at $38.28 on Monday. <a href="https://www.benzinga.com/quote/TIGO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>GLJ Research analyst Gordon Johnson downgraded SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Hold to Sell and maintained the price target of $6.9. SolarEdge shares closed at $23.98 on Monday. <a href="https://www.benzinga.com/quote/SEDG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>GLJ Research analyst Gordon Johnson downgraded Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Hold to Sell and maintained the price target of $0.01. Sunrun shares closed at $9.64 on Monday. <a href="https://www.benzinga.com/quote/RUN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Sophie Karp downgraded Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Sector Weight to Underweight and announced a $31 price target. Enphase Energy shares closed at $44.93 on Monday. <a href="https://www.benzinga.com/quote/ENPH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ENPH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ENPH/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092955/image-265-1024x552.png" alt="" class="wp-image-952304" style="width:594px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092955/image-265-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092955/image-265-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092955/image-265-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092955/image-265.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45968628/wall-streets-most-accurate-analysts-weigh-in-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Markets

Trading Ideas

ENPH

SEDG

TIGO

This Enphase Energy Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Wolfe Research analyst Andy Chen initiates coverage on BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Outperform rating and announces Price Target of $49.

Initiation

BBIO

Wolfe Research Initiates Coverage On BridgeBio Pharma with Outperform Rating, Announces Price Target of $49

<a href="https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease" title="https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease">https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease</a>

Biotech

General

Johnson & Johnson seeks U.S. FDA Approval Of STELARA For The Treatment Of Pediatric Crohn's Disease; Supported By 52-Week Data From The Phase 3UNITI-Jr Study, Submission Aims To Expand STELARA Indication To Treat Children Two Years Of Age And Older

Citigroup analyst Thomas Palmer maintains McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) with a Neutral and lowers the price target from $80 to $77.

Citigroup Maintains Neutral on McCormick & Co, Lowers Price Target to $77

WIIM

SYRE

SYRE stock has given up its prior gain. Spyre Therapeutics shares were trading higher after the company announced interim Phase 1 results from its first-in-human trials of SPY002 and SPY072.

Wolfe Research analyst Andy Chen initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Peer Perform rating.

SRPT

Wolfe Research Initiates Coverage On Sarepta Therapeutics with Peer Perform Rating

JBLU

Reuters Cites Memo From Jetblue Airways Saying Hoped To Reach Break-Even Operating Margin This Year, Which Now Seems Unlikely; Co Has Identified Ways To Combine/Restructure Certain Roles At The Leadership Level; Co Has Been Assessing Size & Scope Of Our Leadership Team; Co Will Continue To Reduce Flying To Match Weaker Demand And In Markets With Multiple Frequencies; Co Is Issuing Updated Travel & Expense Policy This Week Aimed At Reducing Certain Travel Costs

Opinion

Tech

Transforming Personal Data Into Profit Through AI

<a href="https://pr.report/bl3t">Brenmiller Energy Ltd.</a> ("Brenmiller", "Brenmiller Energy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>), a leading global provider of Thermal Energy Storage ("TES") solutions for industrial and utility customers, today announced that a reverse share split of its issued and outstanding ordinary shares, no par value per share (the "Ordinary Shares") at a ratio of 5-for-1 is expected to be implemented after market close on June 18, 2025. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on June 20, 2025 under the Company's existing trading symbol "BNRG".
The reverse share split was approved by the Company's shareholders at the Company's Special General Meeting of Shareholders held on December 5, 2024 (the "Meeting").
Following the reverse share split, the Company's outstanding Ordinary Shares will be reduced from 13,629,259 Ordinary Shares to 2,725,852 Ordinary Shares, proportionate to the approved reverse split ratio. The Company's authorized share capital will not be impacted by the implementation of the reverse share split and will remain 150,000,000 ordinary shares following the consummation of the reverse share split. No fractional shares will be issued as a result of the reverse split. In accordance with the Company's Articles of Association, all fractional shares will be rounded to the nearest whole Ordinary Share such that only shareholders holding fractional consolidated shares of more than half of the number of shares which consolidation constitutes one whole share shall be entitled to receive one consolidated share.

Stock Split

BNRG

Brenmiller Energy Announces 5-For-1 Reverse Share Split; Post-Split Trading To Begin June 20, 2025

Wolfe Research analyst Andy Chen initiates coverage on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Outperform rating and announces Price Target of $55.

Wolfe Research Initiates Coverage On Avidity Biosciences with Outperform Rating, Announces Price Target of $55

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/17053556/banu-0617-900x600-1.png" alt="" class="wp-image-14518" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/17053556/banu-0617-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/17053556/banu-0617-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/17053556/banu-0617-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The restaurant chain's IPO application reveals a complex mix of market trends in the first quarter, including a big rise in customer numbers but lower spending per customer
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Banu International has filed to list in Hong Kong, reporting strong revenue and profit growth in this year's first quarter</li>
<li>The hotpot chain's listing application shows that Chinese consumers were dining out more often in the first quarter, but were spending less per meal</li>
</ul>
By Doug Young
A new Hong Kong IPO application by hotpot chain&nbsp;Banu International Holding Ltd.&nbsp;is offering a complex mix of the latest restaurant trends in China, suggesting consumers are becoming more frugal but also continue to enjoy dining out.
Banu is one of several restaurant operators lining up to list in Hong Kong, in what could be one of the larger such IPOs from that group, raising up to $100 million. The company positions itself at the premium end of the hotpot market, and, indeed, its average spend per customer is about 40% higher than leading chain&nbsp;Haidilao&nbsp;(6862.HK), which caters to more mainstream diners.
Whether its status as a premium brand will help the company in the current economic climate is an open question that could determine whether investors buy into its IPO. Most Chinese restaurant operators reported declining same-store sales last year, largely due to lower spending per customer as consumers became more cautious in China's slowing economy.
It's unclear if that trend has eased this year, since most restaurant operators are listed in Hong Kong, which only requires companies to report their financial results twice a year. Signals from other retailers suggest a return to revenue and same-store sales growth since the start of this year, fueled by growing government initiatives aimed at boosting consumer spending.
One of the few restaurant operators to report first-quarter results is&nbsp;Yum China&nbsp;(YUMC.US; 9987.HK), operator of the KFC chain in China, which said its first-quarter same-store sales growth stabilized and was flat year-on-year, after declining 3% in 2024. But the company reported that its average ticket, similar to average spending-per-customer at traditional sit-down restaurants, dropped 4% year-on-year in the first quarter.
Banu's listing application also suggests that more people resumed dining out in the first quarter, though they continued to spend cautiously. The company's revenue rose 26% year-on-year to 709 million yuan ($99 million) from 564 million yuan a year earlier, though much of that looks attributable to new store openings. The company had 145 restaurants across China at the end of March, up from 111 at the start of 2024.
A deeper dive into some of its metrics shows Banu's customer traffic rose sharply during the first quarter from a year earlier, which helped to offset lower spending per customer. Its number of customers served rose 40% to 5.41 million during the quarter from 3.87 million a year earlier, sharply driving up its table turnover rate to 3.7 times daily from 3.0 times over that period.
But as we've already noted, average spending per customer dropped 5.3% during the quarter to 138 yuan from 148 yuan a year earlier, continuing a downward trend. By comparison, Haidilao's average spending per customer was a far lower 97.5 yuan last year, but was down by a milder 1.6% from 99.1 yuan in 2023.
Restaurants and other retail businesses across China enjoyed a strong post-pandemic rebound in 2023, as consumers engaged in "revenge spending" after three years of frequent store closures and strict limits on their movements both within their hometowns and around China. But that rebound ran out of steam towards the end of 2023 as China's economy slowed and the job and property markets weakened, causing consumers to spend more cautiously.
<h4 class="wp-block-heading">Centralized kitchens</h4>
Banu's financials show it appears to be weathering the slowdown relatively well, despite the weak consumer environment. Like many of its peers, it suffered declining same-store sales last year, with that metric falling 9.9% for the year compared with 2023. But its same-store sales returned to growth in the first quarter, up 2.1% year-on-year.
Banu was founded in Central China's Henan province 2001, making it one of China's earlier chains to focus on the hotpot format that has come to be one of the most popular on the country's dining scene. Henan is still home to the company's largest concentration of restaurants, with 53, or more than a third, scattered around the province.
The company is also notable for its focus on China's smaller cities despite its premium dining status. Among its 145 restaurants, nearly 80% are located in second-tier and lower cities.
Banu cites third-party market data showing that it's China's third-largest hotpot chain, and the category's biggest premium chain with 3.1% of the market. But that market is also quite fragmented, with the top five brands controlling just 8.1% of the overall market. That suggests Banu could emerge as a major player if it can use its scale to keep expanding.
Surprisingly, the company is quite low-key in discussing future expansion plans in its listing document, which would normally be a big selling point for investors. But in such economically uncertain times, it may want to maintain some flexibility. That said, it has been steadily increasing its net store openings in recent year, with 35 new outlets opened last year, up from 25 in 2023 and 11 in 2022.
One of Banu's strengths appears to be its strong reliance on centralized kitchens, which not only lower costs but also provides a more consistent dining experience. The company operates five central kitchens, as well as a specialized ingredient-processing facility.
"We place great emphasis on lean store operations," it said in the listing document. "Supported by our central kitchens and cold chain infrastructure, we have implemented processing and small-batch packaging of ingredients, significantly reducing our restaurant reliance on in-store equipment and labor."
The company's growing scale and reliance on centralized kitchens has helped its profitability, with its restaurant operating margin moving steadily up from 21.3% in 2023 to 23.7% in the first quarter of this year. That improvement has helped the company to steadily increase its profits, including a 58% rise to 55.2 million yuan in the first quarter from 35 million yuan a year earlier.
Haidilao is the most obvious comparison for Banu when trying to calculate a market value, with the former currently trading at a price-to-earnings (P/E) ratio of 16 and price-to-sales (P/S) ratio of 1.74. Similar valuations would value Banu at between 2 billion and 4 billion yuan, providing a tasty new dining choice for Hong Kong investors.

Asia

Restaurants

IPOs

Banu Ladles Up New Hotpot Choice For Hong Kong Investors

<a href="https://www.globenewswire.com/Tracker?data=wkDv0HV_VuHdsniKisTeG-jTldVmG5EW_YfNEnzYdOXx8dBAMZ9jWflmEYhVro3txViGAYji6GT-nUJDaDd5bqary_DfX-lMF_nz8JwWXieZt87xu2NvJFOaJhRPnb-YdO69550vykH3B5DTcC2rowaFvElb7LzBuWg6Rx8Siad_TisCAchvfC447b7gTacP20NiraLytvwkOqd4mG0UE_7qI8a7jzRS9oFOkfq-ukED4y3Rj-8a93z-Cfx7kxg7lV7XBw8tIeAWGtYoqW31yqHaPkTEy4jgpcIBpFuZMPXQQ3981xenxMDTw7iW8zgGdnueB-kUQKybCI6HlkLP5FaRnBJOpKyJ46o2jMyq3vpXquDA6Jsn2X7Ac6Ed0fjVteGk1B6NIGxexlPRtDwy2w==">BioRestorative Therapies, Inc</a>. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026.

Buybacks

BRTX

BioRestorative Therapies Announces $2M Stock Repurchase Program

Wolfe Research analyst Doug Leggate upgrades Comstock Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRK#NYSE">CRK</a>) from Peer Perform to Outperform and announces $34 price target.

Upgrades

Wolfe Research Upgrades Comstock Resources to Outperform, Announces $34 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Canaccord Genuity analyst William Plovanic initiated coverage on Artivion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) with a Buy rating and announced a price target of $35. Artivion shares closed at $28.73 on Monday. <a href="https://www.benzinga.com/quote/AORT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Geoff Meacham initiated coverage on Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Sell rating and announced a price target of $6. Novavax shares closed at $7.03 on Monday. <a href="https://www.benzinga.com/quote/NVAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>China Renaissance analyst Cindy Wang initiated coverage on Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy rating and announced a price target of $353.3. Coinbase shares closed at $261.57 on Monday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Debanjana Chatterjee initiated coverage on Theravance Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy rating and announced a price target of $24. Theravance Biopharma shares closed at $10.75 on Monday. <a href="https://www.benzinga.com/quote/TBPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Johnson Rice analyst Martin Malloy initiated coverage on Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy rating and announced a price target of $20. Venture Global shares closed at $17.40 on Monday. <a href="https://www.benzinga.com/quote/VG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying COIN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/COIN/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-1024x593.png" alt="" class="wp-image-952292" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17092339/image-264.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45968628/wall-streets-most-accurate-analysts-weigh-in-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Comments

Namib Minerals

Namib Minerals (NAMMW) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル